21 Results

People

  1. Hassoun
    Hassoun
  2. Lesokhin
    Lesokhin
  3. Mailankody
    Mailankody
  4. Korde
    Korde
  5. Hultcrantz
    Hultcrantz
  6. Giralt
    Giralt
  7. Chung
    Chung
  8. Landau
    Landau
  9. Landgren
    Landgren
  10. Roshal
    Roshal

Groups

  1. Center for Hematologic Malignancies (21)
  2. Department of Medicine (21)
  3. Hematologic Malignancies Research (21)
  4. Hematologic Malignancies, Division of (21)
  5. Myeloma (21)
  6. Survivorship Research (21)
  7. Sloan Kettering Institute Postdocs (19)
  8. Bone Marrow Transplant (18)
  9. CTCR Scholars (16)
  10. Biostatistics Service (15)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Hani Hassoun"
  4. "Mikhail Roshal"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (7)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (21)
  2. Department of Medicine (21)
  3. Hematologic Malignancies Research (21)
  4. Hematologic Malignancies, Division of (21)
  5. Myeloma (21)
  6. Survivorship Research (21)

More Groups

People
  1. Alexander Lesokhin (21)
  2. Hani Hassoun (21)
  3. Mikhail Roshal (21)
  4. Sham Mailankody (21)
  5. Neha Korde (20)
  6. Malin Hultcrantz (19)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (4)
  4. 2020 (4)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Blood (11)
  2. Leukemia and Lymphoma (2)
  3. American Journal of Hematology (1)
  4. Biology of Blood and Marrow Transplantation (1)
  5. British Journal of Haematology (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Taylor & Francis Group (2)
  3. American Medical Association (1)
  4. American Society of Clinical Oncology (1)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save